Document Detail


Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?
MedLine Citation:
PMID:  19149529     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs) have been prescribed extensively, often in combination with each other. When toxic encephalopathy develops with neuromuscular and autonomic symptoms in a patient taking medication including atypical antipsychotics, it has tended to be diagnosed as neuroleptic malignant syndrome (NMS). However, there have recently been several case reports where the diagnosis of serotonin syndrome is given or raised as a likely differential diagnosis to such cases. In the present review, the author addressed himself to the issues surrounding the neurotoxic reaction to the treatment regimen containing atypical antipsychotics, focusing on the "atypical" forms of NMS and pathophysiological as well as clinical features of serotonin toxicity. Although NMS is idiosyncratic in nature, it appears practically useful to comprehend this syndrome as a spectrum-based concept. Likewise, serotonin toxicity is a broad spectrum of clinical syndromes in close connection with serotomimetic drug use, including varied severity. Some of atypical antipsychotics, i.e., perospirone, aripiprazole, ziprasidone, clozapine, and quetiapine, have been shown to behave as partial agonists at 5-HT1A receptors, providing direct evidence that these atypical antipsychotics are serotomimetic per se. The reciprocal interaction between the dopaminergic and serotonergic systems disturbed by either dopaminergic blockers or serotonergic enhancers leads to the disruption of homeostasis, with typical forms of NMS and serotonin syndrome representing the ends of the common pathophysiological background. The practical and flexible way to consider and manage such cases with updated knowledge derived from basic research should be warranted to be beneficial to our patients.
Authors:
Yuji Odagaki
Related Documents :
1974219 - Pathogenesis and treatment of neuroleptic malignant syndrome.
1997219 - Recurrent neuroleptic malignant syndrome associated with inv dup(15) and mental retarda...
19220899 - A rare case of neuroleptic malignant syndrome presenting with serious hyperthermia trea...
3365089 - Carotid sinus syndrome associated with an occult primary nasopharyngeal carcinoma.
10584199 - Association of inflammatory pseudotumor of the liver and papillon-lefevre syndrome--cas...
19673089 - Catatonia as a risk factor for the development of neuroleptic malignant syndrome: repor...
12200219 - Childhood febrile convulsions--which factors determine the subsequent epilepsy syndrome...
18550699 - New sms mutation leads to a striking reduction in spermine synthase protein function an...
3605139 - Primary sjögren's syndrome with diffuse cerebral vasculitis and lymphocytic interstitia...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current drug safety     Volume:  4     ISSN:  1574-8863     ISO Abbreviation:  Curr Drug Saf     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-19     Completed Date:  2009-03-31     Revised Date:  2012-07-19    
Medline Journal Info:
Nlm Unique ID:  101270895     Medline TA:  Curr Drug Saf     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  84-93     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Faculty of Medicine, Saitama Medical University, Saitama, Japan. odagaki@saitama-med.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antipsychotic Agents / adverse effects*
Humans
Neuroleptic Malignant Syndrome / diagnosis,  etiology*,  physiopathology
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists / adverse effects
Serotonin Syndrome / chemically induced*,  diagnosis,  physiopathology
Serotonin Uptake Inhibitors / adverse effects
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Serotonin 5-HT1 Receptor Agonists; 0/Serotonin Receptor Agonists; 0/Serotonin Uptake Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biodegradable polymer-metal complexes for gene and drug delivery.
Next Document:  Biomarkers, critical disease pathways, drug targets, and alternative medicine in male breast cancer.